Synthesis, characterization, and pharmacological evaluation of new imatinib analogues as antiproliferative agents

Ibtihal Haitham Gani; Zaid Al-Obaidi

doi:10.53730/ijhs.v6nS6.12416

Authors

Ibtihal Haitham Gani
ibtihal.haithim1993@uomustansiriyah.edu.iq
Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Zaid Al-Obaidi Visiting Research Fellow, Aston University, Birmingham, UK | Department of Pharmaceutical Chemistry, College of Pharmacy, University of Alkafeel, Najaf, Iraq | Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Karbala, Iraq

Keywords:

tyrosine kinase, HNMR, MTT, A549, imatinib

Abstract

Abstract
Cancer is the second cause of death after the cardiovascular disease. There are many target receptors for a drug that acts as an anticancer. One of these targets is the tyrosine kinase which is considered one of the most platforms for cancer therapeutics in the recent years. For instance, imatinib is known as a prototype that acts by inhibiting tyrosine kinase receptors. Nevertheless, after one year of receiving imatinib, many patients developed resistance to treatment. Hence, there is an unmet necessity to develop new compounds in an attempt to tackle the resistance issues. In the current work, new imatinib analogues were synthesized with approved attributes. The structures were characterized and confirmed by spectral tools (FTIR,1HNMR, and 13CNMR). Furthermore, the physicochemical properties were acquired with variant reliable techniques (melting point by DSC, Retention factor by TLC, and material description alongside the physical appearance). Moreover, the cytotoxicity of the compound against human lung cancer cell line (A549) was investigated by viability test with an MTT reagent. As a result, compound IIX possesses IC50 =0.623 µM which is three-fold more potent than the reference drug, imatinib (IC50=2.479 µM).

Downloads

Download data is not yet available.

References

Alcivar, M. S. G., Pérez, A. V., Gilert, B. I. C., & Gámez, M. R. (2017). Zeolite in wastewater decontamination as a local development solution. International Journal of Life Sciences, 1(3), 1–13. https://doi.org/10.21744/ijls.v1i3.52

Alpysbaev, K. S., Djuraev, A. M., & Tapilov, E. A. (2021). Reconstructive and restorative interventions at the proximal end of the thigh and pelvic bones in destructive pathological dislocation of the hip in children after hematogenous osteomyelitis. International Journal of Health & Medical Sciences, 4(4), 367-372. https://doi.org/10.21744/ijhms.v4n4.1779

Bernal-Bello, D., Jaenes-Barrios, B., Morales-Ortega, A., Ruiz-Giardin, J. M., García-Bermúdez, V., Frutos-Pérez, B., Farfán-Sedano, A. I., de Ancos-Aracil, C., Bermejo, F., García-Gil, M., Zapatero-Gaviria, A., & San Martín-López, J. V. (2020). Imatinib might constitute a treatment option for lung involvement in COVID-19. Autoimmunity Reviews, 19(7), 102565. https://doi.org/10.1016/J.AUTREV.2020.102565

Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7. https://doi.org/10.1038/SREP42717

García-Gutiérrez, V., & Hernández-Boluda, J. C. (2019). Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. Frontiers in Oncology, 9, 603. https://doi.org/10.3389/FONC.2019.00603/BIBTEX

Gugliotta, G., Castagnetti, F., Breccia, M., Levato, L., D’Adda, M., Stagno, F., Tiribelli, M., Salvucci, M., Fava, C., Martino, B., Cedrone, M., Bocchia, M., Trabacchi, E., Cavazzin, F., Usala, E., Rossi, A. R., Bochicchio, M. T., Soverini, S., Alimena, G., … Rosti, G. (2015). Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica, 100(9), 1146. https://doi.org/10.3324/HAEMATOL.2015.129221

Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., Ortmann, C.-E., Menssen, H. D., Kantarjian, H., O’Brien, S. G., & Druker, B. J. (2017). Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine, 376(10), 917–927. https://doi.org/10.1056/NEJMOA1609324/SUPPL_FILE/NEJMOA1609324_DISCLOSURES.PDF

Ismaeel, S. S., Mahdi, M. F., & Razik, B. M. A. (2020). Molecular Drug Design, Synthesis and Antibacterial study of Novel 4-Oxothiazolidin-3-yl Derivatives. Al Mustansiriyah Journal of Pharmaceutical Sciences, 20(2), 1–10. https://doi.org/10.32947/AJPS.V20I2.691

Kumar, P., Nagarajan, A., & Uchil, P. D. (2018). Analysis of Cell Viability by the MTT Assay. Cold Spring Harbor Protocols, 2018(6), 469–471. https://doi.org/10.1101/PDB.PROT095505

Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., Meyer, T., & Zimmermann, J. (2002). Imatinib: a selective tyrosine kinase inhibitor. European Journal of Cancer, 38, S19–S27. https://doi.org/10.1016/S0959-8049(02)80599-8

Muhsin, Y. F., Alwan, S. M., Kareem Khan, A., & Info, A. (2021). Design, Molecular Docking, Synthesis of Aromatic Amino Acids Linked to Cephalexin. Al Mustansiriyah Journal of Pharmaceutical Sciences, 21(3), 25–34. https://doi.org/10.32947/AJPS.V21I3.794

Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers 2020, Vol. 12, Page 731, 12(3), 731. https://doi.org/10.3390/CANCERS12030731

Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development) - PDF Drive. (n.d.). Retrieved November 12, 2021, from https://www.pdfdrive.com/protein-tyrosine-kinases-from-inhibitors-to-useful-drugs-cancer-drug-discovery-and-development-d156995819.html

Rimassa, L., Danesi, R., Pressiani, T., & Merle, P. (2019). Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treatment Reviews, 77, 20–28. https://doi.org/10.1016/J.CTRV.2019.05.004

Salih, T., & Salih, H. A. (2020). In Silico Design and Molecular Docking Studies of Carbapenem Analogues Targeting Acinetobacter baumannii PBP1A Receptor. Al Mustansiriyah Journal of Pharmaceutical Sciences, 20(3), 35–50. https://doi.org/10.32947/AJPS.V20I3.759

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33. https://doi.org/10.3322/CAAC.21708

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938

Tolosa, L., Donato, M. T., & Gómez-Lechón, M. J. (2015). General cytotoxicity assessment by means of the MTT assay. Methods in Molecular Biology, 1250, 333–348. https://doi.org/10.1007/978-1-4939-2074-7_26/COVER

Viganò, I., Di Giacomo, N., Bozzani, S., Antolini, L., Piazza, R., & Gambacorti Passerini, C. (2014). First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis. American Journal of Hematology, 89(10), E184–E187. https://doi.org/10.1002/AJH.23804

Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., Chen, X., Hou, T., & Cao, D. (2021). ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research, 49(W1), W5–W14. https://doi.org/10.1093/NAR/GKAB255

Yahya, E. B., & Alqadhi, A. M. (2021). Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sciences, 269, 119087. https://doi.org/10.1016/J.LFS.2021.119087